Claudio Scuoppo Wins New ASH Award for Research Disrupted by Global Pandemic
The American Society of Hematology (ASH) has awarded Claudio Scuoppo, PhD, with an ASH Research Restart Award, a new award to addresses the urgent need to help researchers continue their work disrupted by the COVID-19 global pandemic. Dr. Scuoppo, an instructor in the Department of Pathology and Cell Biology in the Institute for Cancer Genetics at Columbia, identifies novel therapies for diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma (NHL).
Like many investigators across universities and medical centers, Dr. Scuoppo’s research shut down abruptly during the spike of the COVID-19 pandemic in New York City last spring. Says Dr. Scuoppo, “This recognition by ASH further strengthens my intention of pursuing an independent research program and will provide resources necessary to finalize and publish my current work during this critical time. I am looking forward to regaining lost progress in my research activities.”
Dr. Scuoppo joined the lab of Riccardo Dalla-Favera, PhD, as a postdoctoral scientist in 2012 and as an instructor in 2017. Dr. Scuoppo focuses on investigating strategies that involve screening FDA-approved drugs for their ability to target known or novel pathway dependencies in Diffuse Large B-cell Lymphoma. He is one of 19 early-career investigators to receive the inaugural ASH award that will support one year of research, including salaries, supplies, training, research expenses, and publication fees, focused on hematologic research.